HIGHLIGHTS
SUMMARY
This phenomenon, currently known as "neo-RAS wild-type (wt)", leads to the appearance of a frametime characterized by RAS wt disease in plasma, which has been described in course of treatment and at the time of disease progression, according to studies. Studies recently aimed to investigate the phenomenon of "neo-RAS wt" suggest an association between clearance of RAS mutations in ctDNA and clinical outcome. The authors provided evidence that in originally RAS mutant mCRC the loss of RAS mutation at failure of first-line treatments strongly impacts on OS, suggesting that the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.